User login
In this supplement to OBG Management a panel of experts discuss the risks and benefits of routine induction of labor (IOL) at 39 weeks. The panelists examine the findings from the ARRIVE trial and the potential impact on real-world practice. The experts also describe their own approach to IOL at 39 weeks and what they see for the future.
Panelists
- Errol R. Norwitz, MD, PhD, MBA (Moderator)
- Aaron B. Caughey, MD, PhD
- John T. Repke, MD
- Sindhu K. Srinivas, MD, MSCE
In this supplement to OBG Management a panel of experts discuss the risks and benefits of routine induction of labor (IOL) at 39 weeks. The panelists examine the findings from the ARRIVE trial and the potential impact on real-world practice. The experts also describe their own approach to IOL at 39 weeks and what they see for the future.
Panelists
- Errol R. Norwitz, MD, PhD, MBA (Moderator)
- Aaron B. Caughey, MD, PhD
- John T. Repke, MD
- Sindhu K. Srinivas, MD, MSCE
In this supplement to OBG Management a panel of experts discuss the risks and benefits of routine induction of labor (IOL) at 39 weeks. The panelists examine the findings from the ARRIVE trial and the potential impact on real-world practice. The experts also describe their own approach to IOL at 39 weeks and what they see for the future.
Panelists
- Errol R. Norwitz, MD, PhD, MBA (Moderator)
- Aaron B. Caughey, MD, PhD
- John T. Repke, MD
- Sindhu K. Srinivas, MD, MSCE
